Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, Obradovic S, Zoric S, Simic M, Penezic Z, Marinkovic J
Institute of Endocrinology, Diabetes Mellitus and Metabolism, University Clinical Center, Belgrade, Yugoslavia.
Clin Endocrinol (Oxf). 1998 Oct;49(4):441-5. doi: 10.1046/j.1365-2265.1998.00536.x.
The goal of our study was to determine the rate of neoplasms in patients with other pituitary adenomas (non-functioning and prolactinomas) in comparison with acromegaly which is known to favour the development of neoplasia.
We reviewed clinical records for 220 patients with acromegaly, 151 patients with non-functioning pituitary adenoma (NF) and 98 patients with prolactinomas. Incidence rates of cancer for patients with pituitary tumours were calculated per person-years of follow-up study. These rates were then compared with sex and age adjusted incidence rates reported by National Tumour Registry. An internal control group of 163 subjects with a non-neoplastic condition, i.e. Graves' disease followed chronically in the same clinic was also studied. The ratios observed to expected were expressed as standardized incidence rates (SIR). The only significant difference between the acromegalic and other pituitary tumours patients was in hypopituitarism, present in 18.2% (acromegaly) 47% (NF) and 18.6% (prolactinomas).
Twenty-three malignant tumours were registered in 19 acromegalics (1 Hodgkin disease, 1 myelogenous leukaemia, 1 lymphocytic leukaemia, 3 papillary thyroid carcinomas, 1 ovarian carcinoma, 2 colorectal carcinoma, 1 renal cell carcinoma, 4 cervical carcinoma, 2 skin cancers, 2 pancreatic carcinoma, 4 breast carcinoma, 1 bladder carcinoma). Three acromegalics harboured two malignancies. Patients with acromegaly had a 3.39-fold increased rate of malignant tumours compared with the general population and a 3.21-fold increased rate compared with our internal control group. Eleven malignant tumours were found in patients with NF-pituitary adenomas and 2 in prolactinoma patients (1 lymphoma, 1 multiple myeloma, 1 colonic cancer, 1 renal cell cancer, 1 stomach cancer, 2 lung cancers, 1 cervix carcinoma, 1 breast cancer, 1 testicular carcinoma and 3 melanoma). Patients with NF pituitary adenomas had a 3.91-fold increased rate of malignant tumours compared with the general population and 4.07-fold increase compared with the internal control group. Patients harbouring prolactinomas did not have an increased incidence rate of malignancy compared with the general population or our internal controls. Female patients with acromegaly and male patients with NF-pituitary adenoma had higher incidences of neoplasia.
We have demonstrated that the overall incidence of malignant tumours in patients with non-functioning pituitary adenomas and acromegaly is significantly higher than expected for general population and for our internal control group.
我们研究的目的是确定其他垂体腺瘤(无功能腺瘤和泌乳素瘤)患者的肿瘤发生率,并与已知易发生肿瘤的肢端肥大症患者进行比较。
我们回顾了220例肢端肥大症患者、151例无功能垂体腺瘤(NF)患者和98例泌乳素瘤患者的临床记录。根据随访研究的人年数计算垂体肿瘤患者的癌症发病率。然后将这些发病率与国家肿瘤登记处报告的按性别和年龄调整后的发病率进行比较。还研究了在同一诊所长期随访的163例非肿瘤性疾病(即格雷夫斯病)患者组成的内部对照组。观察到的与预期的比率表示为标准化发病率(SIR)。肢端肥大症患者与其他垂体肿瘤患者之间唯一显著的差异在于垂体功能减退,肢端肥大症患者中垂体功能减退的发生率为18.2%,NF患者为47%,泌乳素瘤患者为18.6%。
19例肢端肥大症患者登记了23例恶性肿瘤(1例霍奇金病、1例骨髓性白血病、1例淋巴细胞白血病、3例乳头状甲状腺癌、1例卵巢癌、2例结肠直肠癌、1例肾细胞癌、4例宫颈癌、2例皮肤癌、2例胰腺癌、4例乳腺癌、1例膀胱癌)。3例肢端肥大症患者患有两种恶性肿瘤。与普通人群相比,肢端肥大症患者的恶性肿瘤发生率增加了3.39倍,与我们的内部对照组相比增加了3.21倍。NF垂体腺瘤患者中发现11例恶性肿瘤,泌乳素瘤患者中发现2例(1例淋巴瘤、1例多发性骨髓瘤、1例结肠癌、1例肾细胞癌、1例胃癌、2例肺癌、1例宫颈癌、1例乳腺癌、1例睾丸癌和3例黑色素瘤)。与普通人群相比,NF垂体腺瘤患者的恶性肿瘤发生率增加了3.91倍,与内部对照组相比增加了4.07倍。与普通人群或我们的内部对照组相比,患有泌乳素瘤的患者恶性肿瘤发生率没有增加。肢端肥大症女性患者和NF垂体腺瘤男性患者的肿瘤发生率较高。
我们已经证明,无功能垂体腺瘤和肢端肥大症患者的恶性肿瘤总体发生率显著高于普通人群和我们的内部对照组的预期发生率。